ANNOVERA®
The Only Long-Lasting
Birth Control Available
Without A Procedure
It's Time For ANNOVERA
An Alternative Approach To Long-Acting Contraception
Procedure-Free Insertion and Removal1
Predictable Scheduled Bleeding1,2,*
Multiple Visits Not Required
Duration
ANNOVERA
1 YEAR†
IUD/Implant
3-10 YEARS
*5-10% of females experienced unscheduled bleeding and/or spotting for ~1 day or less per 28-day cycle.
†Inserted for 21 continuous days and removed 7 days for 13 cycles.
Demand For Long-Term
Contraception Is Increasing3
Yet many women are not interested in Long-Acting Reversible Contraceptives (LARCs).4
~50% Decline Larcs5
Nearly half of women presented with LARCs reject them due to the procedure required for insertion and removal.
20-30% Have Their IUD Or Implant Removed Within One Year6-8
Common reasons for removal include: irregular bleeding, cramping, expulsions, pain, and other side effects.
References:
- Annovera® [Full Prescribing Information]. Raleigh , NC: Mayne Pharma, Inc; 2022,
- Vieira CS, Fraser IS, Plagianos MG, et al. Bleeding profile associated with 1-year use of the segesterone acetate/ ethinyl estradiol contraceptive vaginal system: pooled analysis from Phase 3 trials. Contraception. 2019;100(6):438-444. doi: 10.1016/j. contraception.2019.07.145.
- Kavanaugh ML, Jerman J. Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014. Contraception. 2018;97:14-21.
- Mansour C. International survey to assess women’s attitudes regarding choice of daily versus nondaily female hormonal contraception. Int J Women’s Health. 2014; 6: 367–375.
- Ipsos Healthcare. Birth Control ATU. November 2020.
- Diedrich JT, Zhao Q, Madden T, et al. Three-year continuation of reversible contraception. Am J Obstet Gynecol, 2015;213:662.e1-8.
- Crosignani PG. Intrauterine devices and intrauterine systems. Human Reproduction Update. 2008 Vol.14, No.3 pp. 197–208, 2008.
- Moray KV, Chaurasia H, Sachin O, et al. A systemic review on clinical effectiveness, side-effect profile, and meta-analysis on continuation rate of etonogestrel contraceptive implant. Reprod Health; 18:4, 2021.